BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25071110)

  • 21. [ALK gene mutations in childhood neuroblastoma].
    Yang CL; Yue LJ; Jiang XP; Wen FQ; Zheng MM
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Oct; 14(10):763-6. PubMed ID: 23092569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncogenic mutations of ALK kinase in neuroblastoma.
    Chen Y; Takita J; Choi YL; Kato M; Ohira M; Sanada M; Wang L; Soda M; Kikuchi A; Igarashi T; Nakagawara A; Hayashi Y; Mano H; Ogawa S
    Nature; 2008 Oct; 455(7215):971-4. PubMed ID: 18923524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of missense mutations on structure and interaction of anaplastic Lymphoma kinase (ALK) in neuroblastom.
    Kanwal H; Khan MH; Rashid H
    Pak J Pharm Sci; 2013 May; 26(3):611-6. PubMed ID: 23625438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking.
    Mazot P; Cazes A; Boutterin MC; Figueiredo A; Raynal V; Combaret V; Hallberg B; Palmer RH; Delattre O; Janoueix-Lerosey I; Vigny M
    Oncogene; 2011 Apr; 30(17):2017-25. PubMed ID: 21242967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency and Prognostic Impact of
    Bellini A; Pötschger U; Bernard V; Lapouble E; Baulande S; Ambros PF; Auger N; Beiske K; Bernkopf M; Betts DR; Bhalshankar J; Bown N; de Preter K; Clément N; Combaret V; Font de Mora J; George SL; Jiménez I; Jeison M; Marques B; Martinsson T; Mazzocco K; Morini M; Mühlethaler-Mottet A; Noguera R; Pierron G; Rossing M; Taschner-Mandl S; Van Roy N; Vicha A; Chesler L; Balwierz W; Castel V; Elliott M; Kogner P; Laureys G; Luksch R; Malis J; Popovic-Beck M; Ash S; Delattre O; Valteau-Couanet D; Tweddle DA; Ladenstein R; Schleiermacher G
    J Clin Oncol; 2021 Oct; 39(30):3377-3390. PubMed ID: 34115544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.
    Heukamp LC; Thor T; Schramm A; De Preter K; Kumps C; De Wilde B; Odersky A; Peifer M; Lindner S; Spruessel A; Pattyn F; Mestdagh P; Menten B; Kuhfittig-Kulle S; Künkele A; König K; Meder L; Chatterjee S; Ullrich RT; Schulte S; Vandesompele J; Speleman F; Büttner R; Eggert A; Schulte JH
    Sci Transl Med; 2012 Jul; 4(141):141ra91. PubMed ID: 22764207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging importance of ALK in neuroblastoma.
    Azarova AM; Gautam G; George RE
    Semin Cancer Biol; 2011 Oct; 21(4):267-75. PubMed ID: 21945349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas.
    Yan B; Kuick CH; Lim M; Venkataraman K; Tennakoon C; Loh E; Lian D; Leong MY; Lakshmanan M; Tergaonkar V; Sung WK; Soh SY; Chang KT
    PLoS One; 2014; 9(9):e106575. PubMed ID: 25188507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia.
    Zhu YM; Foroni L; McQuaker IG; Papaioannou M; Haynes A; Russell HH
    Br J Cancer; 1999 Mar; 79(7-8):1151-7. PubMed ID: 10098750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic ALK alterations in primary and relapsed neuroblastoma.
    Rosswog C; Fassunke J; Ernst A; Schömig-Markiefka B; Merkelbach-Bruse S; Bartenhagen C; Cartolano M; Ackermann S; Theissen J; Blattner-Johnson M; Jones B; Schramm K; Altmüller J; Nürnberg P; Ortmann M; Berthold F; Peifer M; Büttner R; Westermann F; Schulte JH; Simon T; Hero B; Fischer M
    Br J Cancer; 2023 Apr; 128(8):1559-1571. PubMed ID: 36807339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of ALK germline mutation (3605delG) in pediatric anaplastic medulloblastoma.
    Coco S; De Mariano M; Valdora F; Servidei T; Ridola V; Andolfo I; Oberthuer A; Tonini GP; Longo L
    J Hum Genet; 2012 Oct; 57(10):682-4. PubMed ID: 22810114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential Impact of
    O'Donohue T; Gulati N; Mauguen A; Kushner BH; Shukla N; Rodriguez-Sanchez MI; Bouvier N; Roberts S; Basu E; Cheung NK; Modak S
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy.
    Martinsson T; Eriksson T; Abrahamsson J; Caren H; Hansson M; Kogner P; Kamaraj S; Schönherr C; Weinmar J; Ruuth K; Palmer RH; Hallberg B
    Cancer Res; 2011 Jan; 71(1):98-105. PubMed ID: 21059859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
    Huang D; Kim DW; Kotsakis A; Deng S; Lira P; Ho SN; Lee NV; Vizcarra P; Cao JQ; Christensen JG; Kim TM; Sun JM; Ahn JS; Ahn MJ; Park K; Mao M
    Genomics; 2013 Sep; 102(3):157-62. PubMed ID: 23434628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted Therapy for Neuroblastoma: ALK Inhibitors.
    Schulte JH; Schulte S; Heukamp LC; Astrahantseff K; Stephan H; Fischer M; Schramm A; Eggert A
    Klin Padiatr; 2013 Nov; 225(6):303-8. PubMed ID: 24166094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogenic mutations of ALK in neuroblastoma.
    Ogawa S; Takita J; Sanada M; Hayashi Y
    Cancer Sci; 2011 Feb; 102(2):302-8. PubMed ID: 21205076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.
    Eleveld TF; Oldridge DA; Bernard V; Koster J; Colmet Daage L; Diskin SJ; Schild L; Bentahar NB; Bellini A; Chicard M; Lapouble E; Combaret V; Legoix-Né P; Michon J; Pugh TJ; Hart LS; Rader J; Attiyeh EF; Wei JS; Zhang S; Naranjo A; Gastier-Foster JM; Hogarty MD; Asgharzadeh S; Smith MA; Guidry Auvil JM; Watkins TB; Zwijnenburg DA; Ebus ME; van Sluis P; Hakkert A; van Wezel E; van der Schoot CE; Westerhout EM; Schulte JH; Tytgat GA; Dolman ME; Janoueix-Lerosey I; Gerhard DS; Caron HN; Delattre O; Khan J; Versteeg R; Schleiermacher G; Molenaar JJ; Maris JM
    Nat Genet; 2015 Aug; 47(8):864-71. PubMed ID: 26121087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germline gain-of-function mutations of ALK disrupt central nervous system development.
    de Pontual L; Kettaneh D; Gordon CT; Oufadem M; Boddaert N; Lees M; Balu L; Lachassinne E; Petros A; Mollet J; Wilson LC; Munnich A; Brugière L; Delattre O; Vekemans M; Etchevers H; Lyonnet S; Janoueix-Lerosey I; Amiel J
    Hum Mutat; 2011 Mar; 32(3):272-6. PubMed ID: 21972109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations.
    Davidsson J; Paulsson K; Lindgren D; Lilljebjörn H; Chaplin T; Forestier E; Andersen MK; Nordgren A; Rosenquist R; Fioretos T; Young BD; Johansson B
    Leukemia; 2010 May; 24(5):924-31. PubMed ID: 20237506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of the transforming potential of novel anaplastic lymphoma kinase point mutants.
    McDuff FK; Lim SV; Dalbay M; Turner SD
    Mol Carcinog; 2013 Jan; 52(1):79-83. PubMed ID: 22086496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.